M Mahler

Summary

Publications

  1. doi request reprint Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases
    Michael Mahler
    INOVA Diagnostics, Inc San Diego, CA 32131 1638, USA
    Autoimmun Rev 11:642-5. 2012
  2. doi request reprint PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease
    Michael Mahler
    INOVA Diagnostics, Inc, San Diego, CA, United States Electronic address
    Clin Chim Acta 424:267-73. 2013
  3. pmc The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases
    Michael Mahler
    INOVA Diagnostics, Inc, 9900 Old Grove Road, San Diego, CA 32131 1638, USA
    Clin Dev Immunol 2012:494356. 2012
  4. doi request reprint Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases
    Michael Mahler
    Department of Research, INOVA Diagnostics Inc, San Diego, California, USA
    J Rheumatol 39:2104-10. 2012
  5. doi request reprint Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome
    Michael Mahler
    INOVA Diagnostics, Inc, San Diego, CA 32131 1638, USA
    Autoimmun Rev 12:313-7. 2012
  6. doi request reprint The clinical significance of autoantibodies to the proliferating cell nuclear antigen (PCNA)
    Michael Mahler
    INOVA Diagnostics, Inc San Diego, CA 32131 1638, USA
    Autoimmun Rev 11:771-5. 2012
  7. doi request reprint Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies
    M Mahler
    INOVA Diagnostics, Inc, San Diego, CA 32131 1638, USA
    Clin Chim Acta 413:719-26. 2012
  8. doi request reprint Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope
    M Mahler
    Development and Production, Dr Fooke Laboratorien, Mainstrasse 85, 41469 Neuss, Germany
    Rheumatol Int 32:691-8. 2012
  9. ncbi request reprint Sm peptides in differentiation of autoimmune diseases
    Michael Mahler
    INOVA Diagnostics Inc, San Diego, California, USA
    Adv Clin Chem 54:109-28. 2011
  10. doi request reprint Performance evaluation of a novel chemiluminescence assay for detection of anti-GBM antibodies: an international multicenter study
    Michael Mahler
    INOVA Diagnostics, Inc San Diego, CA, USA
    Nephrol Dial Transplant 27:243-52. 2012

Detail Information

Publications15

  1. doi request reprint Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases
    Michael Mahler
    INOVA Diagnostics, Inc San Diego, CA 32131 1638, USA
    Autoimmun Rev 11:642-5. 2012
    ....
  2. doi request reprint PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease
    Michael Mahler
    INOVA Diagnostics, Inc, San Diego, CA, United States Electronic address
    Clin Chim Acta 424:267-73. 2013
    ..We determined if PR3-ANCA is a biomarker that differentiates ulcerative colitis (UC) from Crohn's disease (CrD)...
  3. pmc The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases
    Michael Mahler
    INOVA Diagnostics, Inc, 9900 Old Grove Road, San Diego, CA 32131 1638, USA
    Clin Dev Immunol 2012:494356. 2012
    ..This immunoadsorption method has the potential to overcome a significant limitation of the ANA HEp-2 assay. The present paper summarizes the current knowledge about anti-DFS70 antibodies and their clinical impact on ANA testing...
  4. doi request reprint Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases
    Michael Mahler
    Department of Research, INOVA Diagnostics Inc, San Diego, California, USA
    J Rheumatol 39:2104-10. 2012
    ....
  5. doi request reprint Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome
    Michael Mahler
    INOVA Diagnostics, Inc, San Diego, CA 32131 1638, USA
    Autoimmun Rev 12:313-7. 2012
    ..Moreover, we present a suggested guideline for future studies to better understand and verify the clinical utility of anti-β(2)GP1-D1 antibodies...
  6. doi request reprint The clinical significance of autoantibodies to the proliferating cell nuclear antigen (PCNA)
    Michael Mahler
    INOVA Diagnostics, Inc San Diego, CA 32131 1638, USA
    Autoimmun Rev 11:771-5. 2012
    ....
  7. doi request reprint Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies
    M Mahler
    INOVA Diagnostics, Inc, San Diego, CA 32131 1638, USA
    Clin Chim Acta 413:719-26. 2012
    ..We evaluated novel chemiluminescence assays (CIAs) for PR3- and MPO-ANCA detection and investigated their utility for disease activity monitoring...
  8. doi request reprint Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope
    M Mahler
    Development and Production, Dr Fooke Laboratorien, Mainstrasse 85, 41469 Neuss, Germany
    Rheumatol Int 32:691-8. 2012
    ..Although an association between anti-C22 reactivity and SLEDAI score was observed in one center, measurement of anti-C22 autoantibodies is likely not appropriate for measuring global disease activity...
  9. ncbi request reprint Sm peptides in differentiation of autoimmune diseases
    Michael Mahler
    INOVA Diagnostics Inc, San Diego, California, USA
    Adv Clin Chem 54:109-28. 2011
    ..Additionally, a meta-analysis focused on recent data analyzes the prevalence of anti-Sm antibodies in SLE...
  10. doi request reprint Performance evaluation of a novel chemiluminescence assay for detection of anti-GBM antibodies: an international multicenter study
    Michael Mahler
    INOVA Diagnostics, Inc San Diego, CA, USA
    Nephrol Dial Transplant 27:243-52. 2012
    ..The objective of our study was to carefully analyze the performance characteristics of a novel anti-glomerular basement membrane (GBM) chemiluminescence immunoassay (CIA)...
  11. doi request reprint Novel diagnostic and clinical aspects of anti-PCNA antibodies detected by novel detection methods
    M Mahler
    Dr Fooke Laboratorien, Neuss, Germany
    Lupus 19:1527-33. 2010
    ..The specific association of anti-PCNA antibodies with systemic lupus erythematosus was not confirmed in our study...
  12. pmc Improved serological differentiation between systemic lupus erythematosus and mixed connective tissue disease by use of an SmD3 peptide-based immunoassay
    M Mahler
    Dr Fooke Laboratorien GmbH, Mainstr 85, 41469 Neuss, Germany
    Clin Diagn Lab Immunol 12:107-13. 2005
    ..Finally, we conclude that the recently identified SmD peptide containing a symmetrical dimethylarginine at position 112 of D3 represents a promising tool for the detection of a highly specific subpopulation of anti-Sm antibodies...
  13. doi request reprint Latest update on the Ro/SS-A autoantibody system
    J Schulte-Pelkum
    Dr Fooke Laboratorien GmbH, Neuss, Germany
    Autoimmun Rev 8:632-7. 2009
    ..It was concluded that Ro60 (SS-A) and Ro52 represent two distinct autoantibody systems and that separate detection is desirable in a clinical diagnostic setting...
  14. ncbi request reprint Serological and clinical characterization of anti-dsDNA and anti-PM/Scl double-positive patients
    M Mahler
    Dr Fooke Laboratorien GmbH, Neuss, Germany
    Ann N Y Acad Sci 1109:311-21. 2007
    ..Clinically, anti-dsDNA(+)/anti-PM/Scl(+) patients may define a small subgroup of SLE patients with additional features of systemic sclerosis...
  15. ncbi request reprint Development and evaluation of a rapid assay for the diagnosis of immunoglobulin E-mediated type I allergies
    R Lucassen
    Dr Fooke Laboratorien GmbH, Neuss, Germany
    J Investig Allergol Clin Immunol 18:223-4. 2008